Structural basis of metallo-β-lactamase resistance to taniborbactam
Antimicrobial Agents and Chemotherapy · 07.02.2024 · 68 (2)
DOI: 10.1128/aac.01168-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 07.02.2024. Verfasst von Salvador I Drusin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, Argentina. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Borinic Acids, Carboxylic Acids. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación, HHS | National Institutes of Health.
Abstract (Originalsprache)
The design of inhibitors against metallo-β-lactamases (MBLs), the largest family of carbapenemases, has been a strategic goal in designing novel antimicrobial therapies. In this regard, the development of bicyclic boronates, such as taniborbactam (TAN) and xeruborbactam, is a major achievement that may help in overcoming the threat of MBL-producing and carbapenem-resistant Gram-negative pathogens. Of concern, a recent report has shown that New Delhi MBL-9 (NDM-9) escapes the inhibitory action of TAN by a single amino acid substitution with respect to New Delhi MBL-1 (NDM-1), the most widely disseminated MBL. Here, we report a docking and computational analysis that identifies that “escape variants” against TAN can arise by disruption of the electrostatic interaction of negative charges in the active site loops of MBLs with the N-(2-aminoethyl)cyclohexylamine side chain of TAN. These changes result in non-productive binding modes of TAN that preclude reaction with the MBLs, a phenomenon that is not restricted to NDM-9. This analysis demonstrates that single amino acid substitutions in non-essential residues in MBL loops can unexpectedly elicit resistance to TAN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, Argentina.
- Emerging Antibiotic Resistance, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
- Division of Intensive care unit, University hospitals of Geneva, Geneva, Switzerland.
- Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), Fribourg, Switzerland.
- Research Service and GRECC, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
- Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
ORCID-Profile: Salvador I Drusin, Christophe Le Terrier, Laurent Poirel, Robert A Bonomo, Alejandro J Vila, Diego M Moreno
Förderung
- NIAID NIH HHS
- Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación
- HHS | National Institutes of Health
Zitieren
APA
Drusin, S. I., Le Terrier, C., Poirel, L., Bonomo, R. A., Vila, A. J., & Moreno, D. M. (2024). Structural basis of metallo-β-lactamase resistance to taniborbactam. Antimicrobial Agents and Chemotherapy, 68(2). https://doi.org/10.1128/aac.01168-23
Vancouver
Drusin SI, Le Terrier C, Poirel L, Bonomo RA, Vila AJ, Moreno DM. Structural basis of metallo-β-lactamase resistance to taniborbactam. Antimicrobial Agents and Chemotherapy. 2024;68(2). doi:10.1128/aac.01168-23
BibTeX
@article{Drusin2024,
author = {Drusin, Salvador I and Le Terrier, Christophe and Poirel, Laurent and Bonomo, Robert A and Vila, Alejandro J and Moreno, Diego M},
title = {Structural basis of metallo-β-lactamase resistance to taniborbactam},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
volume = {68},
number = {2},
doi = {10.1128/aac.01168-23}
}
EUVIMED